« Return to News | Miscellaneous

NovaCardia Sees Positive Results with treatment for heart failure

Monday, June 25, 2007 11:04 AM

NovaCardia reported positive preliminary results from a phase III trial of KW-3902 for the treatment of acute congestive heart failure (CHF). This double-blind, randomized trial enrolled 304 subjects with CHF and renal impairment. Subjects received placebo or 10, 20 or 30 milligram doses of intravenous KW- 3902, administered daily for up to three days. All subjects received intravenous furosemide.

The primary endpoint was the proportion of subjects in the categories of treatment success, treatment failure or no change. The 30 mg dose of KW-3902 appeared to be the most efficacious, with higher rates of treatment success and lower rates of treatment failure compared to placebo.

Twenty-four hours post-treatment, self-reported marked or moderate improvement in dyspnea was reported in 66% of the KW-3902 (30 mg) group compared to 51% of the placebo group. No statistically significant differences in adverse events were reported between the groups. The 30 mg dose of KW-3902 was determined to be the optimal dose for NovaCardia’s two 600-subject phase III trials, dubbed PROTECT-1 and PROTECT-2.

Both trials are enrolling subjects in the U.S., Canada, Europe, Israel and Russia.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.